UBS initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $50 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Ideaya’s “transformative” multi-billion dollar uveal melanoma therapy is underappreciated at current share levels, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences initiated with an Overweight at Cantor Fitzgerald
- Ideaya Biosciences management to meet with Oppenheimer
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- Ideaya Biosciences price target lowered to $52 from $54 at Wedbush
- Ideaya Biosciences should be bought on weakness, says Citi